CD47 and cancer: Evaluation of CD47-SIRPα axis revealed: a) diffuse CD47 expression in the majority of cases both in the TC and the IF (Figure 6Aiii–iv and Figure S4A), and similarly to the expression of PD-L1, the levels of CD47 were lower in patients who received neoadjuvant therapy (Figure 6C and Figure S7A, p-value < 0.05); b) SIRPα was detected both in stromal and cancer cells in the majority of PDAC cases, independently of the neoadjuvant chemotherapy (Figure 6v,vi and Figure S4A).